Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 22, 2013 - Issue 10
Submit an article Journal homepage
589
Views
10
CrossRef citations to date
0
Altmetric
Reviews

Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies

Claudio GasperiniMultiple Sclerosis Center, S Camillo-Forlanini, Neurosciences, Circonvallazione Gianicolense 87, Rome 00152, [email protected]
,
Shalom HaggiagMultiple Sclerosis Center, S Camillo-Forlanini, Neurosciences, Circonvallazione Gianicolense 87, Rome 00152, [email protected]
&
Serena RuggieriUniversity of Rome ‘La Sapienza’, Dipartimento di Neurologia e Psichiatria, VIAle dell'università 30, Rome 00198, Italy
Pages 1243-1253 | Published online: 16 Jul 2013

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jenny J Feng & Daniel Ontaneda. (2017) Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies. Degenerative Neurological and Neuromuscular Disease 7, pages 31-45.
Read now

Articles from other publishers (9)

Francisco Gascón-Giménez, Carmen Alcalá, Lluís Ramió-Torrentà, Paloma Montero, Jorge Matías-Guiu, Irene Gómez-Estevez, Celia Oreja-Guevara, Sara Gil-Perotín, Yolanda Blanco, María Carcelén, Carlos Quintanilla-Bordás, Lucienne Costa, Luisa Maria Villar, Jose Enrique Martínez-Rodriguez, José Andrés Domínguez, Carmen Calles, Inés González, Javier Sotoca, Agustin Oterino, Celia Lucas-Jimenez, Francisco Pérez-Miralles & Bonaventura Casanova. (2023) Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience. Frontiers in Neurology 14.
Crossref
Erica Costantini, Eva Masciarelli, Laura Casorri, Marco Di Luigi & Marcella Reale. (2022) Medicinal herbs and multiple sclerosis: Overview on the hard balance between new therapeutic strategy and occupational health risk. Frontiers in Cellular Neuroscience 16.
Crossref
Mahdi Barazesh, Shiva Mohammadi, Yadollah Bahrami, Pooneh Mokarram, Mohammad Hossein Morowvat, Massoud Saidijam, Morteza Karimipoor, Soudabeh Kavousipour, Amir Reza Vosoughi & Korosh Khanaki. (2021) CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models. Current Gene Therapy 21:2, pages 130-148.
Crossref
Elodie Martin, Marie-Stéphane Aigrot, Roland GrenninglohBruno Stankoff, Catherine Lubetzki, Ursula Boschert & Bernard Zalc. (2020) Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair. Brain Plasticity 5:2, pages 123-133.
Crossref
Shuanghui Yang, Huan Li, Ling Xu, Zhenhan Deng, Wei Han, Yanting Liu, Wenqi Jiang & Youli Zu. (2018) Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies. Molecular Therapy - Nucleic Acids 13, pages 164-175.
Crossref
Cong Wu, Wei Wan, Ji Zhu, Hai Jin, Tiejun Zhao & Huafei Li. (2017) Induction of potent apoptosis by an anti-CD20 aptamer via the crosslink of membrane CD20 on non-Hodgkin's lymphoma cells. RSC Advances 7:9, pages 5158-5166.
Crossref
Zahra Tolou-Ghamari. (2016) Efficacy and Toxicity of Rituximab in Multiple Sclerosis. Archives of Neuroscience 3:1.
Crossref
Jeffrey T. Guptill, Madhu Soni & Matthew N. Meriggioli. (2015) Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics 13:1, pages 118-131.
Crossref
Abigail E. Russi & Melissa A. Brown. (2015) The meninges: new therapeutic targets for multiple sclerosis. Translational Research 165:2, pages 255-269.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.